Altiris Therapeutics

Altiris Therapeutics is a clinical-stage biotechnology company specializing in the development of small molecule inhibitors for oncology indications. The company's research focuses on targeting the Bcl-2 family of proteins and the CXCR4/CXCL12 axis to overcome treatment resistance and prevent tumor metastasis. Its lead candidate, AT-101, is a pan-Bcl-2 inhibitor that has been evaluated in Phase 2 clinical trials for glioblastoma and other cancers. In 2021, Altiris was acquired by Vivesto (formerly Oasmia Pharmaceutical) to expand its portfolio of cancer therapies. The company's technology originated from research conducted at the University of Pittsburgh.